Cisbio Bioassays introduces new HTRF^® SIRT1 assay at DDT USA

Cisbio US will be introducing the HTRF^® SIRT1 assay at the 13th Annual Drug Discovery & Development of Innovative Therapeutics World Congress, being held August 4-7 2008 in Boston, Massachusetts.

HTRF SIRT1 assay is a homogeneous solution which measures the SIRT1 deacetylation activity. MAb based, HTRF SIRT1 assay allows for high reproducibility. Amenable to 384 low-volume format (20µL) and consuming low enzyme and substrate, HTRF SIRT1 is precisely suited for High Throughput inhibitor Screening applications

Cisbio Bioassays is an established provider of products and services for high-throughput drug discovery screening. We offer a comprehensive range of reagents to study targets related to oncology, inflammation, metabolic and cardiovascular disease, and central nervous system disorders. Cisbio Bioassays products are used by pharmaceutical and biotechnology companies as well as CROs.

Visit us at booth #636 to learn more.